Patients with schizophrenia experience high rates of cardiometabolic comorbidities such as obesity, dyslipidemia, hypertension, type 2 diabetes, and cardiovascular disease. The etiology of these comorbidities is multifactorial, arising from a complex interplay of intrinsic and extrinsic factors, including genetic predispositions, physical inactivity, unhealthy diet, high smoking rates, poorer socioeconomic status, as well as antipsychotic medication side effects. Beyond the devastating medical sequelae, these comorbidities also contribute to medication non-adherence, low self-esteem, decreased quality of life, and worse cognitive functioning.
Related content
Professor Dr. Merete Nordentoft introduces her work with the population of children of parents with schizophrenia. She also highlights the model implemented in Denmark, called VIA family, and why it is important to focus on children of parents living with schizophrenia.
Professor Dr. Christoph Correll highlights the recent innovations in the pharmacological treatment of schizophrenia.
Dr. Marco Solmi introduces what the mortality gap is and why there is a mortality gap in schizophrenia.